GDC-2394

GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation.


Cat. No.: EX-A6966	Purity: >98%

	Chemical structure of GDC-2394

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	2185	Inquire
500mg	3250	Inquire
1g	4650	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2238822-07-4
Purity	>98%
Formula	C20H25N5O4S
Mol Weight	431.509
Color	White to off-white
State	solid powder
Solubility	Soluble in DMSO 50 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20℃ 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24. [2]. Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.
CoA	CoA of GDC-2394


		Search